ID   IGROV-1
AC   CVCL_1304
SY   Igrov-1; IGROV 1; IGR-OV1; IGROV1; Igrov1; IGR.OV1; IGROV; OV1/P; OV1/p; OV1-P
DR   BTO; BTO:0002575
DR   CLO; CLO_0006672
DR   EFO; EFO_0005385
DR   CLDB; cl2627
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   BioGRID_ORCS_Cell_line; 897
DR   BioSample; SAMN03470926
DR   BioSample; SAMN10988218
DR   cancercelllines; CVCL_1304
DR   Cell_Model_Passport; SIDM00151
DR   ChEMBL-Cells; CHEMBL3307502
DR   ChEMBL-Targets; CHEMBL613984
DR   Cosmic; 688100
DR   Cosmic; 875857
DR   Cosmic; 897430
DR   Cosmic; 905968
DR   Cosmic; 920360
DR   Cosmic; 947357
DR   Cosmic; 1044236
DR   Cosmic; 1092607
DR   Cosmic; 1093557
DR   Cosmic; 1102823
DR   Cosmic; 1175880
DR   Cosmic; 1305334
DR   Cosmic; 1312353
DR   Cosmic; 1707557
DR   Cosmic; 1709252
DR   Cosmic; 1998449
DR   Cosmic; 2464669
DR   Cosmic-CLP; 905968
DR   DepMap; ACH-000966
DR   EGA; EGAS00001000610
DR   EGA; EGAS00001000978
DR   GDSC; 905968
DR   GEO; GSM2127
DR   GEO; GSE23440
DR   GEO; GSE25191
DR   GEO; GSM50218
DR   GEO; GSM50281
DR   GEO; GSM313715
DR   GEO; GSM711720
DR   GEO; GSM743472
DR   GEO; GSM743496
DR   GEO; GSM750827
DR   GEO; GSM799361
DR   GEO; GSM799424
DR   GEO; GSM844567
DR   GEO; GSM844568
DR   GEO; GSM844569
DR   GEO; GSM844570
DR   GEO; GSM846360
DR   GEO; GSM851919
DR   GEO; GSM887160
DR   GEO; GSM888232
DR   GEO; GSM1153432
DR   GEO; GSM1181284
DR   GEO; GSM1181285
DR   GEO; GSM1291142
DR   GEO; GSM1374571
DR   GEO; GSM1669930
DR   GEO; GSM2124667
DR   IARC_TP53; 21072
DR   IARC_TP53; 21125
DR   IARC_TP53; 30209
DR   LiGeA; CCLE_165
DR   Lonza; 175
DR   Millipore; SCC203
DR   NCI-DTP; IGR-OV1
DR   PharmacoDB; IGROV1_654_2019
DR   PRIDE; PXD003668
DR   PRIDE; PXD005942
DR   PRIDE; PXD005946
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_1304
DR   PubChem_Cell_line; CVCL_1304
DR   SKY/M-FISH/CGH; 2739
DR   Wikidata; Q54897382
RX   PubMed=2041050;
RX   PubMed=3335022;
RX   PubMed=8564971;
RX   PubMed=9443634;
RX   PubMed=9488600;
RX   PubMed=9636834;
RX   PubMed=10700174;
RX   PubMed=10817511;
RX   PubMed=12960427;
RX   PubMed=15748285;
RX   PubMed=16319398;
RX   PubMed=17088437;
RX   PubMed=19372543;
RX   PubMed=20164919;
RX   PubMed=22068913;
RX   PubMed=22328975;
RX   PubMed=22347499;
RX   PubMed=22384151;
RX   PubMed=22460905;
RX   PubMed=22628656;
RX   PubMed=22710073;
RX   PubMed=23415752;
RX   PubMed=23839242;
RX   PubMed=23856246;
RX   PubMed=23913215;
RX   PubMed=23933261;
RX   PubMed=24023729;
RX   PubMed=24279929;
RX   PubMed=24670534;
RX   PubMed=25230021;
RX   PubMed=25485619;
RX   PubMed=25877200;
RX   PubMed=25984343;
RX   PubMed=26589293;
RX   PubMed=27235858;
RX   PubMed=27377824;
RX   PubMed=27397505;
RX   PubMed=27561551;
RX   PubMed=27807467;
RX   PubMed=28196595;
RX   PubMed=30485824;
RX   PubMed=30894373;
RX   PubMed=30971826;
RX   PubMed=31068700;
RX   PubMed=31978347;
RX   PubMed=32612269;
RX   PubMed=35839778;
WW   https://dtp.cancer.gov/discovery_development/nci-60/cell_list.htm
WW   https://strap.nci.nih.gov/celline_detail.php?sample_id=26
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Part of: KuDOS 95 cell line panel.
CC   Part of: MD Anderson Cell Lines Project.
CC   Part of: NCI-60 cancer cell line panel.
CC   Part of: OCCP ovarian cancer cell line panel.
CC   Population: Caucasian.
CC   Doubling time: 30 hours (PubMed=25984343); ~23 hours (PubMed=10817511); 28 +- 1 hours (PubMed=9636834); 28 hours (PubMed=9488600); 31 hours (NCI-DTP=IGR-OV1); 19.53 hours (JWGray panel).
CC   HLA typing: A*24:02:01,33:01; B*49:01; C*07; DPB1*05:01; DQB1*03; DRB1*11,11 (PubMed=15748285).
CC   HLA typing: A*24:02,33:03; B*45:01,49:01; C*07:01,07:01; DQA1*01:02,01:02 (PubMed=26589293).
CC   Microsatellite instability: Instable (MSI-high) (PubMed=31068700; Sanger).
CC   Sequence variation: Mutation; HGNC; 1100; BRCA1; Simple; p.Lys654Serfs*47 (c.1961delA); ClinVar=VCV000037438; Zygosity=Heterozygous (PubMed=17088437; PubMed=25230021; Cosmic-CLP=905968).
CC   Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Lys1108Argfs*11 (c.3323delA) (p.Gln1107fs) (c.3320delA); ClinVar=VCV000225716; Zygosity=Unspecified (PubMed=25230021).
CC   Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Arg38Cys (c.112C>T); ClinVar=VCV000376493; Zygosity=Heterozygous (Cosmic-CLP=905968; DepMap=ACH-000966).
CC   Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Ter1069TrpinsLysAspAsn (c.3207A>G); Zygosity=Heterozygous (Cosmic-CLP=905968; DepMap=ACH-000966).
CC   Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Thr319fs*1 (c.955_958delACTT) (p.VL317fs) (V317fs*3); Zygosity=Heterozygous (PubMed=17088437; PubMed=25230021; Cosmic-CLP=905968; DepMap=ACH-000966).
CC   Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Val654Cysfs*4 (c.1959delA); Zygosity=Heterozygous (Cosmic-CLP=905968; DepMap=ACH-000966).
CC   Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Gly231Alafs*10 (c.692delG); ClinVar=VCV001756201; Zygosity=Heterozygous (PubMed=17088437; Cosmic-CLP=905968; DepMap=ACH-000966).
CC   Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Leu495Pro (c.1484T>C); Zygosity=Heterozygous (PubMed=17088437; Cosmic-CLP=905968; DepMap=ACH-000966).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser90Leufs*59 (c.267dupC) (c.267_268insC); ClinVar=VCV000634762; Zygosity=Heterozygous (PubMed=17088437; PubMed=24023729; PubMed=25230021; Cosmic-CLP=905968; DepMap=ACH-000966).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr126Cys (c.377A>G); ClinVar=VCV000458541; Zygosity=Heterozygous (PubMed=17088437; PubMed=24023729; PubMed=25230021; Cosmic-CLP=905968; DepMap=ACH-000966).
CC   Omics: Array-based CGH.
CC   Omics: CNV analysis.
CC   Omics: CRISPR phenotypic screen.
CC   Omics: Deep exome analysis.
CC   Omics: Deep proteome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Fluorescence phenotype profiling.
CC   Omics: Genome sequenced.
CC   Omics: lncRNA expression profiling.
CC   Omics: Metabolome analysis.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: shRNA library screening.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=0.69%; Native American=0%; East Asian, North=0%; East Asian, South=1.43%; South Asian=4.55%; European, North=46.04%; European, South=47.29% (PubMed=30894373).
CC   Misspelling: IGROV-4; PubMed=12960427.
CC   Misspelling: IGR-OV1-RU; Cosmic=1175880.
CC   Derived from site: In situ; Ovary; UBERON=UBERON_0000992.
ST   Source(s): Cosmic-CLP=905968; Millipore=SCC203; PubMed=19372543; PubMed=25230021; PubMed=25877200; PubMed=30485824
ST   Amelogenin: X
ST   CSF1PO: 11,12,13,14,15,16 (Millipore=SCC203)
ST   CSF1PO: 11,13 (PubMed=19372543; PubMed=30485824)
ST   CSF1PO: 11,13,14,15 (Cosmic-CLP=905968)
ST   CSF1PO: 11,13,15 (PubMed=25877200)
ST   CSF1PO: 11,16 (PubMed=25230021)
ST   D13S317: 8,10
ST   D16S539: 10,11,12,13 (Millipore=SCC203)
ST   D16S539: 11,12 (Cosmic-CLP=905968; PubMed=19372543; PubMed=25877200)
ST   D16S539: 11,13 (PubMed=30485824)
ST   D16S539: 12 (PubMed=25230021)
ST   D18S51: 14,15,16 (Millipore=SCC203)
ST   D18S51: 14,16,17 (PubMed=25230021)
ST   D18S51: 15,16 (PubMed=25877200)
ST   D19S433: 13,14
ST   D21S11: 26,29.2,30.2 (PubMed=25230021)
ST   D21S11: 26,30.2 (PubMed=25877200; PubMed=30485824)
ST   D21S11: 26,30.2,31.2 (Millipore=SCC203)
ST   D2S1338: 17,25
ST   D3S1358: 13,14,15 (Millipore=SCC203; PubMed=25230021; PubMed=25877200)
ST   D3S1358: 13,15 (PubMed=19372543)
ST   D5S818: 11,12,13 (Millipore=SCC203)
ST   D5S818: 12 (PubMed=25877200; PubMed=30485824)
ST   D5S818: 12,13 (Cosmic-CLP=905968; PubMed=19372543; PubMed=25230021)
ST   D7S820: 9.1,10.1,11.1 (PubMed=25230021)
ST   D7S820: 9.3,10.1 (PubMed=30485824)
ST   D7S820: 10 (PubMed=25877200)
ST   D7S820: 10,10.1,10.3,11.1 (Millipore=SCC203)
ST   D7S820: 11 (Cosmic-CLP=905968)
ST   D8S1179: 13,14,15,16,17 (Millipore=SCC203)
ST   D8S1179: 14,16 (PubMed=25230021; PubMed=25877200)
ST   FGA: 20,21,26 (PubMed=25230021)
ST   FGA: 21,25,26 (Millipore=SCC203)
ST   FGA: 21,26 (PubMed=25877200)
ST   Penta D: 8,10
ST   Penta E: 13,17
ST   TH01: 7,9.3
ST   TPOX: 8,11 (Millipore=SCC203; PubMed=19372543; PubMed=25230021; PubMed=25877200; PubMed=30485824)
ST   TPOX: 8,11,12 (Cosmic-CLP=905968)
ST   vWA: 16,17,20,21,22 (Millipore=SCC203)
ST   vWA: 16,17,20,22 (PubMed=25230021)
ST   vWA: 17,21 (Cosmic-CLP=905968; PubMed=19372543; PubMed=30485824)
ST   vWA: 17,21,22 (PubMed=25877200)
DI   NCIt; C7979; Ovarian endometrioid adenocarcinoma
DI   ORDO; Orphanet_454723; Endometrioid carcinoma of ovary
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   47Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 02-05-24; Version: 45
//
RX   PubMed=2041050; DOI=10.1093/jnci/83.11.757;
RA   Monks A., Scudiero D.A., Skehan P., Shoemaker R.H., Paull K.D.,
RA   Vistica D.T., Hose C.D., Langley J., Cronise P., Vaigro-Wolff A.,
RA   Gray-Goodrich M., Campbell H., Mayo J.G., Boyd M.R.;
RT   "Feasibility of a high-flux anticancer drug screen using a diverse
RT   panel of cultured human tumor cell lines.";
RL   J. Natl. Cancer Inst. 83:757-766(1991).
//
RX   PubMed=3335022;
RA   Alley M.C., Scudiero D.A., Monks A., Hursey M.L., Czerwinski M.J.,
RA   Fine D.L., Abbott B.J., Mayo J.G., Shoemaker R.H., Boyd M.R.;
RT   "Feasibility of drug screening with panels of human tumor cell lines
RT   using a microculture tetrazolium assay.";
RL   Cancer Res. 48:589-601(1988).
//
RX   PubMed=8564971;
RA   Perego P., Giarola M., Righetti S.C., Supino R., Caserini C.,
RA   Delia D., Pierotti M.A., Miyashita T., Reed J.C., Zunino F.;
RT   "Association between cisplatin resistance and mutation of p53 gene and
RT   reduced bax expression in ovarian carcinoma cell systems.";
RL   Cancer Res. 56:556-562(1996).
//
RX   PubMed=9443634; DOI=10.1007/s002800050727;
RA   Ma J.-G., Maliepaard M., Kolker H.J., Verweij J., Schellens J.H.M.;
RT   "Abrogated energy-dependent uptake of cisplatin in a
RT   cisplatin-resistant subline of the human ovarian cancer cell line
RT   IGROV-1.";
RL   Cancer Chemother. Pharmacol. 41:186-192(1998).
//
RX   PubMed=9488600; DOI=10.1007/s002800050744;
RA   Ma J.-G., Maliepaard M., Nooter K., Boersma A.W.M., Verweij J., Stoter G.,
RA   Schellens J.H.M.;
RT   "Synergistic cytotoxicity of cisplatin and topotecan or SN-38 in a
RT   panel of eight solid-tumor cell lines in vitro.";
RL   Cancer Chemother. Pharmacol. 41:307-316(1998).
//
RX   PubMed=9636834; DOI=10.1023/A:1008265012435;
RA   Perego P., Romanelli S., Carenini N., Magnani I., Leone R.,
RA   Bonetti A., Paolicchi A., Zunino F.;
RT   "Ovarian cancer cisplatin-resistant cell lines: multiple changes
RT   including collateral sensitivity to taxol.";
RL   Ann. Oncol. 9:423-430(1998).
//
RX   PubMed=10700174; DOI=10.1038/73432;
RA   Ross D.T., Scherf U., Eisen M.B., Perou C.M., Rees C., Spellman P.T.,
RA   Iyer V.R., Jeffrey S.S., van de Rijn M., Waltham M.C., Pergamenschikov A.,
RA   Lee J.C.F., Lashkari D., Shalon D., Myers T.G., Weinstein J.N.,
RA   Botstein D., Brown P.O.;
RT   "Systematic variation in gene expression patterns in human cancer cell
RT   lines.";
RL   Nat. Genet. 24:227-235(2000).
//
RX   PubMed=10817511; DOI=10.1054/bjoc.2000.1224; PMCID=PMC2374505;
RA   Erba E., Bergamaschi D., Bassano L., Ronzoni S., Di Liberti G.,
RA   Muradore I., Vignati S., Faircloth G.T., Jimeno J.M., D'Incalci M.;
RT   "Isolation and characterization of an IGROV-1 human ovarian cancer
RT   cell line made resistant to Ecteinascidin-743 (ET-743).";
RL   Br. J. Cancer 82:1732-1739(2000).
//
RX   PubMed=12960427; DOI=10.1091/mbc.E03-05-0279; PMCID=PMC266758;
RA   Schaner M.E., Ross D.T., Ciaravino G., Sorlie T., Troyanskaya O.G.,
RA   Diehn M., Wang Y.C., Duran G.E., Sikic T.L., Caldeira S., Skomedal H.,
RA   Tu I.-P., Hernandez-Boussard T., Johnson S.W., O'Dwyer P.J., Fero M.J.,
RA   Kristensen G.B., Borresen-Dale A.-L., Hastie T., Tibshirani R.,
RA   van de Rijn M., Teng N.N.H., Longacre T.A., Botstein D., Brown P.O.,
RA   Sikic B.I.;
RT   "Gene expression patterns in ovarian carcinomas.";
RL   Mol. Biol. Cell 14:4376-4386(2003).
//
RX   PubMed=15748285; DOI=10.1186/1479-5876-3-11; PMCID=PMC555742;
RA   Adams S., Robbins F.-M., Chen D., Wagage D., Holbeck S.L.,
RA   Morse H.C. 3rd, Stroncek D., Marincola F.M.;
RT   "HLA class I and II genotype of the NCI-60 cell lines.";
RL   J. Transl. Med. 3:11.1-11.8(2005).
//
RX   PubMed=16319398; DOI=10.1074/mcp.M500140-MCP200;
RA   Stewart J.J., White J.T., Yan X.-W., Collins S.J., Drescher C.W.,
RA   Urban N.D., Hood L.E., Lin B.-Y.;
RT   "Proteins associated with cisplatin resistance in ovarian cancer cells
RT   identified by quantitative proteomic technology and integrated with
RT   mRNA expression levels.";
RL   Mol. Cell. Proteomics 5:433-443(2006).
//
RX   PubMed=17088437; DOI=10.1158/1535-7163.MCT-06-0433; PMCID=PMC2705832;
RA   Ikediobi O.N., Davies H.R., Bignell G.R., Edkins S., Stevens C.,
RA   O'Meara S., Santarius T., Avis T., Barthorpe S., Brackenbury L.,
RA   Buck G., Butler A.P., Clements J., Cole J., Dicks E., Forbes S.,
RA   Gray K., Halliday K., Harrison R., Hills K., Hinton J., Hunter C.,
RA   Jenkinson A., Jones D., Kosmidou V., Lugg R., Menzies A.,
RA   Mironenko T., Parker A., Perry J., Raine K.M., Richardson D.,
RA   Shepherd R., Small A., Smith R., Solomon H., Stephens P.J.,
RA   Teague J.W., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Reinhold W.C., Weinstein J.N., Stratton M.R., Futreal P.A., Wooster R.;
RT   "Mutation analysis of 24 known cancer genes in the NCI-60 cell line
RT   set.";
RL   Mol. Cancer Ther. 5:2606-2612(2006).
//
RX   PubMed=19372543; DOI=10.1158/1535-7163.MCT-08-0921; PMCID=PMC4020356;
RA   Lorenzi P.L., Reinhold W.C., Varma S., Hutchinson A.A., Pommier Y.,
RA   Chanock S.J., Weinstein J.N.;
RT   "DNA fingerprinting of the NCI-60 cell line panel.";
RL   Mol. Cancer Ther. 8:713-724(2009).
//
RX   PubMed=20164919; DOI=10.1038/nature08768; PMCID=PMC3145113;
RA   Bignell G.R., Greenman C.D., Davies H.R., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=22068913; DOI=10.1073/pnas.1111840108; PMCID=PMC3219108;
RA   Gillet J.-P., Calcagno A.M., Varma S., Marino M., Green L.J.,
RA   Vora M.I., Patel C., Orina J.N., Eliseeva T.A., Singal V.,
RA   Padmanabhan R., Davidson B., Ganapathi R., Sood A.K., Rueda B.R.,
RA   Ambudkar S.V., Gottesman M.M.;
RT   "Redefining the relevance of established cancer cell lines to the
RT   study of mechanisms of clinical anti-cancer drug resistance.";
RL   Proc. Natl. Acad. Sci. U.S.A. 108:18708-18713(2011).
//
RX   PubMed=22328975; DOI=10.1158/2159-8290.CD-11-0170; PMCID=PMC3274821;
RA   Hanrahan A.J., Schultz N., Westfal M.L., Sakr R.A., Giri D.D.,
RA   Scarperi S., Janakiraman M., Olvera N., Stevens E.V., She Q.-B.,
RA   Aghajanian C., King T.A., de Stanchina E., Spriggs D.R., Heguy A.,
RA   Taylor B.S., Sander C., Rosen N., Levine D.A., Solit D.B.;
RT   "Genomic complexity and AKT dependence in serous ovarian cancer.";
RL   Cancer Discov. 2:56-67(2012).
//
RX   PubMed=22347499; DOI=10.1371/journal.pone.0031628; PMCID=PMC3276511;
RA   Ruan X.-Y., Kocher J.-P.A., Pommier Y., Liu H.-F., Reinhold W.C.;
RT   "Mass homozygotes accumulation in the NCI-60 cancer cell lines as
RT   compared to HapMap trios, and relation to fragile site location.";
RL   PLoS ONE 7:E31628-E31628(2012).
//
RX   PubMed=22384151; DOI=10.1371/journal.pone.0032096; PMCID=PMC3285665;
RA   Lee J.-S., Kim Y.K., Kim H.J., Hajar S., Tan Y.L., Kang N.-Y., Ng S.H.,
RA   Yoon C.N., Chang Y.-T.;
RT   "Identification of cancer cell-line origins using fluorescence
RT   image-based phenomic screening.";
RL   PLoS ONE 7:E32096-E32096(2012).
//
RX   PubMed=22460905; DOI=10.1038/nature11003; PMCID=PMC3320027;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=22628656; DOI=10.1126/science.1218595; PMCID=PMC3526189;
RA   Jain M., Nilsson R., Sharma S., Madhusudhan N., Kitami T., Souza A.L.,
RA   Kafri R., Kirschner M.W., Clish C.B., Mootha V.K.;
RT   "Metabolite profiling identifies a key role for glycine in rapid
RT   cancer cell proliferation.";
RL   Science 336:1040-1044(2012).
//
RX   PubMed=22710073; DOI=10.1016/j.ygyno.2012.06.017; PMCID=PMC3432677;
RA   Korch C.T., Spillman M.A., Jackson T.A., Jacobsen B.M., Murphy S.K.,
RA   Lessey B.A., Jordan V.C., Bradford A.P.;
RT   "DNA profiling analysis of endometrial and ovarian cell lines reveals
RT   misidentification, redundancy and contamination.";
RL   Gynecol. Oncol. 127:241-248(2012).
//
RX   PubMed=23415752; DOI=10.1016/j.molonc.2012.12.007; PMCID=PMC4106023;
RA   Stordal B., Timms K., Farrelly A., Gallagher D., Busschots S.,
RA   Renaud M., Thery J., Williams D., Potter J., Tran T., Korpanty G.,
RA   Cremona M., Carey M.S., Li J., Li Y., Aslan O., O'Leary J.J.,
RA   Mills G.B., Hennessy B.T.;
RT   "BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one
RT   functionally deleterious BRCA1 mutation.";
RL   Mol. Oncol. 7:567-579(2013).
//
RX   PubMed=23839242; DOI=10.1038/ncomms3126; PMCID=PMC3715866;
RA   Domcke S., Sinha R., Levine D.A., Sander C., Schultz N.;
RT   "Evaluating cell lines as tumour models by comparison of genomic
RT   profiles.";
RL   Nat. Commun. 4:2126.1-2126.10(2013).
//
RX   PubMed=23856246; DOI=10.1158/0008-5472.CAN-12-3342; PMCID=PMC4893961;
RA   Abaan O.D., Polley E.C., Davis S.R., Zhu Y.-L.J., Bilke S., Walker R.L.,
RA   Pineda M.A., Gindin Y., Jiang Y., Reinhold W.C., Holbeck S.L.,
RA   Simon R.M., Doroshow J.H., Pommier Y., Meltzer P.S.;
RT   "The exomes of the NCI-60 panel: a genomic resource for cancer biology
RT   and systems pharmacology.";
RL   Cancer Res. 73:4372-4382(2013).
//
RX   PubMed=23913215; DOI=10.1007/978-1-62703-547-7_12;
RA   Li L.-S., Liu J., Yu W., Lou X.-Y., Huang B.-D., Lin B.-Y.;
RT   "Deep transcriptome profiling of ovarian cancer cells using
RT   next-generation sequencing approach.";
RL   Methods Mol. Biol. 1049:139-169(2013).
//
RX   PubMed=23933261; DOI=10.1016/j.celrep.2013.07.018;
RA   Moghaddas Gholami A., Hahne H., Wu Z.-X., Auer F.J., Meng C.,
RA   Wilhelm M., Kuster B.;
RT   "Global proteome analysis of the NCI-60 cell line panel.";
RL   Cell Rep. 4:609-620(2013).
//
RX   PubMed=24023729; DOI=10.1371/journal.pone.0072162; PMCID=PMC3762837;
RA   Anglesio M.S., Wiegand K.C., Melnyk N., Chow C., Salamanca C.M.,
RA   Prentice L.M., Senz J., Yang W., Spillman M.A., Cochrane D.R.,
RA   Shumansky K., Shah S.P., Kalloger S.E., Huntsman D.G.;
RT   "Type-specific cell line models for type-specific ovarian cancer
RT   research.";
RL   PLoS ONE 8:E72162-E72162(2013).
//
RX   PubMed=24279929; DOI=10.1186/2049-3002-1-20; PMCID=PMC4178206;
RA   Dolfi S.C., Chan L.L.-Y., Qiu J., Tedeschi P.M., Bertino J.R.,
RA   Hirshfield K.M., Oltvai Z.N., Vazquez A.;
RT   "The metabolic demands of cancer cells are coupled to their size and
RT   protein synthesis rates.";
RL   Cancer Metab. 1:20.1-20.13(2013).
//
RX   PubMed=24670534; DOI=10.1371/journal.pone.0092047; PMCID=PMC3966786;
RA   Varma S., Pommier Y., Sunshine M., Weinstein J.N., Reinhold W.C.;
RT   "High resolution copy number variation data in the NCI-60 cancer cell
RT   lines from whole genome microarrays accessible through CellMiner.";
RL   PLoS ONE 9:E92047-E92047(2014).
//
RX   PubMed=25230021; DOI=10.1371/journal.pone.0103988; PMCID=PMC4167545;
RA   Beaufort C.M., Helmijr J.C.A., Piskorz A.M., Hoogstraat M.,
RA   Ruigrok-Ritstier K., Besselink N., Murtaza M., van IJcken W.F.J.,
RA   Heine A.A.J., Smid M., Koudijs M.J., Brenton J.D., Berns E.M.J.J.,
RA   Helleman J.;
RT   "Ovarian cancer cell line panel (OCCP): clinical importance of in
RT   vitro morphological subtypes.";
RL   PLoS ONE 9:E103988-E103988(2014).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=25984343; DOI=10.1038/sdata.2014.35; PMCID=PMC4432652;
RA   Cowley G.S., Weir B.A., Vazquez F., Tamayo P., Scott J.A., Rusin S.,
RA   East-Seletsky A., Ali L.D., Gerath W.F.J., Pantel S.E., Lizotte P.H.,
RA   Jiang G.-Z., Hsiao J., Tsherniak A., Dwinell E., Aoyama S., Okamoto M.,
RA   Harrington W., Gelfand E.T., Green T.M., Tomko M.J., Gopal S.,
RA   Wong T.C., Li H.-B., Howell S., Stransky N., Liefeld T., Jang D.,
RA   Bistline J., Meyers B.H., Armstrong S.A., Anderson K.C.,
RA   Stegmaier K., Reich M., Pellman D., Boehm J.S., Mesirov J.P.,
RA   Golub T.R., Root D.E., Hahn W.C.;
RT   "Parallel genome-scale loss of function screens in 216 cancer cell
RT   lines for the identification of context-specific genetic
RT   dependencies.";
RL   Sci. Data 1:140035-140035(2014).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5; PMCID=PMC4653878;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=27235858; DOI=10.1016/j.ygyno.2016.05.028; PMCID=PMC4961516;
RA   Hernandez L., Kim M.K., Lyle L.T., Bunch K.P., House C.D., Ning F.,
RA   Noonan A.M., Annunziata C.M.;
RT   "Characterization of ovarian cancer cell lines as in vivo models for
RT   preclinical studies.";
RL   Gynecol. Oncol. 142:332-340(2016).
//
RX   PubMed=27377824; DOI=10.1038/sdata.2016.52; PMCID=PMC4932877;
RA   Mestdagh P., Lefever S., Volders P.-J., Derveaux S., Hellemans J.,
RA   Vandesompele J.;
RT   "Long non-coding RNA expression profiling in the NCI60 cancer cell
RT   line panel using high-throughput RT-qPCR.";
RL   Sci. Data 3:160052-160052(2016).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017; PMCID=PMC4967469;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=27561551; DOI=10.1038/ncomms12645; PMCID=PMC5007461;
RA   Coscia F., Watters K.M., Curtis M., Eckert M.A., Chiang C.-Y.,
RA   Tyanova S., Montag A., Lastra R.R., Lengyel E., Mann M.;
RT   "Integrative proteomic profiling of ovarian cancer cell lines reveals
RT   precursor cell associated proteins and functional status.";
RL   Nat. Commun. 7:12645.1-12645.14(2016).
//
RX   PubMed=27807467; DOI=10.1186/s13100-016-0078-4; PMCID=PMC5087121;
RA   Zampella J.G., Rodic N., Yang W.R., Huang C.R.L., Welch J.,
RA   Gnanakkan V.P., Cornish T.C., Boeke J.D., Burns K.H.;
RT   "A map of mobile DNA insertions in the NCI-60 human cancer cell
RT   panel.";
RL   Mob. DNA 7:20.1-20.11(2016).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005; PMCID=PMC5501076;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=30485824; DOI=10.1016/j.celrep.2018.10.096; PMCID=PMC6481945;
RA   Papp E., Hallberg D., Konecny G.E., Bruhm D.C., Adleff V., Noe M.,
RA   Kagiampakis I., Palsgrove D., Conklin D., Kinose Y., White J.R.,
RA   Press M.F., Drapkin R.I., Easwaran H., Baylin S.B., Slamon D.J.,
RA   Velculescu V.E., Scharpf R.B.;
RT   "Integrated genomic, epigenomic, and expression analyses of ovarian
RT   cancer cell lines.";
RL   Cell Rep. 25:2617-2633(2018).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747; PMCID=PMC6445675;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=30971826; DOI=10.1038/s41586-019-1103-9;
RA   Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M.,
RA   Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R.,
RA   Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P.,
RA   van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L.,
RA   Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.;
RT   "Prioritization of cancer therapeutic targets using CRISPR-Cas9
RT   screens.";
RL   Nature 568:511-516(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3; PMCID=PMC6697103;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. 3rd, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=31978347; DOI=10.1016/j.cell.2019.12.023; PMCID=PMC7339254;
RA   Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. 3rd,
RA   Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K.,
RA   Jedrychowski M.P., Golji J., Porter D.A., Rejtar T., Wang Y.K.,
RA   Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A.,
RA   Sellers W.R., Gygi S.P.;
RT   "Quantitative proteomics of the Cancer Cell Line Encyclopedia.";
RL   Cell 180:387-402.e16(2020).
//
RX   PubMed=32612269; DOI=10.1038/s41598-020-67533-1; PMCID=PMC7329846;
RA   De Haven Brandon A.K., Box G., Hallsworth A., Court W., Matthews N.,
RA   Herodek B., Arteagabeitia A.B., Valenti M., Kirkin V.;
RT   "Identification of ovarian high-grade serous carcinoma cell lines that
RT   show estrogen-sensitive growth as xenografts in immunocompromised
RT   mice.";
RL   Sci. Rep. 10:10799-10799(2020).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010; PMCID=PMC9387775;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//